US Stock Market Move | Launch of a new platform to provide weight-loss drug services for self-paying patients. Shares of Novo Nordisk A/S Sponsored ADR Class B(NVO.US) surged nearly 4%.

On Wednesday, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) officially launched NovoCare Pharmacy, a new platform specifically designed to provide weight loss medication services for self-paying patients, directly challenging Eli Lilly's LillyDirect platform launched last year. As of the time of writing, Novo Nordisk A/S Sponsored ADR Class B rose nearly 4% to $90.91, while Lilly rose over 1% to $920. Through NovoCare, Novo Nordisk A/S Sponsored ADR Class B will provide its flagship weight loss medication Wegovy (semaglutide) to uninsured patients, or those with commercial insurance that does not cover obesity treatment. The medication will be available in five doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. Novo Nordisk A/S Sponsored ADR Class B stated that patients can receive the GLP-1 weight loss medication through NovoCare Pharmacy for a discounted monthly cash payment of $499, and enjoy home delivery service.